Skip to main content

Main menu

  • Home
  • Current Issue
  • Content
    • Current Issue
    • Early Access
    • Multimedia
    • Podcast
    • Collections
    • Past Issues
    • Articles by Subject
    • Articles by Type
    • Supplements
    • Plain Language Summaries
    • Calls for Papers
  • Info for
    • Authors
    • Reviewers
    • Job Seekers
    • Media
  • About
    • Annals of Family Medicine
    • Editorial Staff & Boards
    • Sponsoring Organizations
    • Copyrights & Permissions
    • Announcements
  • Engage
    • Engage
    • e-Letters (Comments)
    • Subscribe
    • Podcast
    • E-mail Alerts
    • Journal Club
    • RSS
    • Annals Forum (Archive)
  • Contact
    • Contact Us
  • Careers

User menu

  • My alerts

Search

  • Advanced search
Annals of Family Medicine
  • My alerts
Annals of Family Medicine

Advanced Search

  • Home
  • Current Issue
  • Content
    • Current Issue
    • Early Access
    • Multimedia
    • Podcast
    • Collections
    • Past Issues
    • Articles by Subject
    • Articles by Type
    • Supplements
    • Plain Language Summaries
    • Calls for Papers
  • Info for
    • Authors
    • Reviewers
    • Job Seekers
    • Media
  • About
    • Annals of Family Medicine
    • Editorial Staff & Boards
    • Sponsoring Organizations
    • Copyrights & Permissions
    • Announcements
  • Engage
    • Engage
    • e-Letters (Comments)
    • Subscribe
    • Podcast
    • E-mail Alerts
    • Journal Club
    • RSS
    • Annals Forum (Archive)
  • Contact
    • Contact Us
  • Careers
  • Follow annalsfm on Twitter
  • Visit annalsfm on Facebook
Research ArticleOriginal Research

Subclinical Hypothyroidism and the Risk of Hypercholesterolemia

William J. Hueston and William S. Pearson
The Annals of Family Medicine July 2004, 2 (4) 351-355; DOI: https://doi.org/10.1370/afm.79
William J. Hueston
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William S. Pearson
MHA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Published eLetters

If you would like to comment on this article, click on Submit a Response to This article, below. We welcome your input.

Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

Jump to comment:

  • REPLY
    Wiliam J. Hueston
    Published on: 18 August 2004
  • Hypothyroidism and Dyslipidemia
    Richard L. Garrison
    Published on: 12 August 2004
  • So What Does A Mildly Elevated TSH Mean?
    Joseph E. Scherger
    Published on: 02 August 2004
  • Published on: (18 August 2004)
    Page navigation anchor for REPLY
    REPLY
    • Wiliam J. Hueston, Charleston, SC

    Dr. Garrison raises some important points in his letter that I feel need to be clarified. First, while Dr. Garrison derides our study as an "outlier," there is a key difference between our study and previous ones examining this issue. The important difference is that our study reflects a population-based sampling frame. The only previous study that comes close to being population-based is the Colorado Thyroid Study, bu...

    Show More

    Dr. Garrison raises some important points in his letter that I feel need to be clarified. First, while Dr. Garrison derides our study as an "outlier," there is a key difference between our study and previous ones examining this issue. The important difference is that our study reflects a population-based sampling frame. The only previous study that comes close to being population-based is the Colorado Thyroid Study, but this study was not population-based since study participants were self-selected attendees at health fairs across the state; one must assume that people who attend health fairs are representative of the general populations (which I do not believe) and that those who migrate to a "thyroid testing" booth are a random sample of that group. Other studies that showed improvement in well-being with thyroid supplementation in patients with elevated TSH were frequently populated with patients who had previous thyroid abnormalities (most often hyperthyroid that had been treated with radioactive iodine) and patients referred to endocrinologists, presumably because of symptoms (otherwise why would they be at an endocrinologist's office?). Based on the skewed populations in previous studies looking at cholesterol and thyroid disease, I believe that the supposition that these people were asymptomatic is likely false. What these previous studies likely showed is that if a patient exhibits symptoms similar to hypothyroidism and has a high TSH, thyroid supplementation may be appropriate. But the ability to generalize these results to the truly asymptomatic individual (the vast majority of people who have subclinical hypothyroidism) is still open to question.

    Second, the contention that the connection between subclinical hypothyroidism and hyperlipidemia or heart disease is well established is not supported by the evidence. A recent scientific review and guidelines for diagnosis and management of subclinical thyroid disease sponsored by the Endocrine Society (1) stated that the strength of evidence between subclinical hypothyroidism and heart disease was insufficient and that there was no evidence of benefits of treatment. For cholesterol and subclinical hypothyroidism, most evidence also was judged to be insufficient. Consequently, the association between subclinical hypothyroidism and heart disease or risk factors for heart disease, such as hyperlipidemia, is far from settled.

    As noted in a previous letter from Dr. Scherger, the lack of evidence that subclinical hypothyroidism is directly harmful has not stopped industry- supported experts from taking what little data there is and drawing conclusions. However, I would urge us to be more cautious in our interpretation of studies performed on narrowly-drawn patient populations.

    William Hueston, MD

    References: 1. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease. JAMA 2004:291:228-238.

    Competing interests:   None declared

    Show Less
    Competing Interests: None declared.
  • Published on: (12 August 2004)
    Page navigation anchor for Hypothyroidism and Dyslipidemia
    Hypothyroidism and Dyslipidemia
    • Richard L. Garrison, Baytown, TX

    Hueston and Pearson perform a substantial work in this article. Nevertheless, I ask whether the science has already progressed beyond the simple association of hypothyroidism and dyslipidemia. Elevated TSH with normal T4 (regretably in this case, total rather than free) can no longer be properly referred to as subclinical hypothyroidism, except to establish a link with a historical literature. This particular brand of...

    Show More

    Hueston and Pearson perform a substantial work in this article. Nevertheless, I ask whether the science has already progressed beyond the simple association of hypothyroidism and dyslipidemia. Elevated TSH with normal T4 (regretably in this case, total rather than free) can no longer be properly referred to as subclinical hypothyroidism, except to establish a link with a historical literature. This particular brand of hypothyroidism is associated with dyslipidemias in a number of other articles, making this article an outlier in that regard. Far more importantly, articles reporting treatment of these patients with T4 demonstrate improvement of lipid profiles in addition to the improved wellbeing cited by the authors. Even more importantly, independent of whether hypothyroidism, subclinical or otherwise, has an effect on lipids, it has an effect on cardiovascular risk, increases arterial intimal thickening that is reversed by T4 treatment, and adversely affects endothelial function in a manner reversed by T4 treatment. In short, treatment makes a difference, so this is not subclinical disease.

    We now have so many examples of treatments that reduce cardiovascular risk or have demonstrated direct effects on the actual lesion of atherosclerosis (T4, folate, Omega-3 FA, allicin to name several) that function independently of changes in lipids due to treatment, that it is no longer wise to evaluate potential benefits of treatment by looking only at the earliest surrogate marker, lipids. Our experience with clofibrate should be enough to teach us that improvement in that parameter alone is not enough, and the effects of statins above and beyond that accountable by lipid changes take us further down that road. I hope that further work in the area will look more at effects on the lesion of atherosclerosis and its reversal, and better still, on clinically significant outcomes, than on surrogate markers.

    Competing interests:   None declared

    Show Less
    Competing Interests: None declared.
  • Published on: (2 August 2004)
    Page navigation anchor for So What Does A Mildly Elevated TSH Mean?
    So What Does A Mildly Elevated TSH Mean?
    • Joseph E. Scherger, San Diego, CA USA

    Hueston and Pearson have made a valuable contribution to the controversy over mildly elevated TSH levels in euthyroid patients. Is the so-called "subclinical hypothyroidism" really subclinical? Advocates for treating mildly elevated TSH levels (myself included) have been convinced that this condition has true clinical consequences and is better termed mild hypothyroidism. I recently attended a half day continuing educa...

    Show More

    Hueston and Pearson have made a valuable contribution to the controversy over mildly elevated TSH levels in euthyroid patients. Is the so-called "subclinical hypothyroidism" really subclinical? Advocates for treating mildly elevated TSH levels (myself included) have been convinced that this condition has true clinical consequences and is better termed mild hypothyroidism. I recently attended a half day continuing education course (funded by the makers of Synthroid) in which leading academic thyroidologists advocated the lowering of the upper limit of normal TSH to 3.5. They cited numerous clinical consequences of elevated TSH levels, including hyperlipidemia. Hueston and Pearson, using a community population data set, show that the differences in lipids among people with mildly elevated TSH levels are small compared to people with normal TSH levels. From their study, it appears that the supposed hyperlipidemia of elevated TSH levels has been exaggerated.

    This study should not be used to dispute any clinical consequences of elevated TSH levels. Many questions remain. Are the mildly increased total cholesterol and triglyceride levels significant to the health of the population? Even small differences matter when the condition is common and leads to the most common cause of death. Do patients with elevated TSH levels respond as readily to lipid lowering therapy? Would a small dose of levothyroxine eliminate the need for a lipid lowering drug, or reduce the dose of drug if needed? What about weight loss? With the epidemic of overweight and obesity, do patients with elevated TSH levels have more difficulty losing weight if untreated? What about fertility? What about mood disorders? It is tempting to think that normal T4 levels are what matters, but elevated TSH levels imply that autoimmune hypothyroidism is developing and does early treatment matter? Who should get anti-thyroid antibody levels? There are many questions to answer in this area in which the problem and potential comorbidities are common and have major health consequences.

    More reseach like this needs to be done to put the issue of elevated TSH levels into clinical perspective. We need less belief and emotion and more good science. It would help if the NIH or other research agencies independent of commercialism supported this work. Hueston and Pearson lead by example.

    Competing interests:   None declared

    Show Less
    Competing Interests: None declared.
PreviousNext
Back to top

In this issue

The Annals of Family Medicine: 2 (4)
The Annals of Family Medicine: 2 (4)
Vol. 2, Issue 4
1 Jul 2004
  • Table of Contents
  • Index by author
  • The Issue in Brief
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Annals of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Subclinical Hypothyroidism and the Risk of Hypercholesterolemia
(Your Name) has sent you a message from Annals of Family Medicine
(Your Name) thought you would like to see the Annals of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 17 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Subclinical Hypothyroidism and the Risk of Hypercholesterolemia
William J. Hueston, William S. Pearson
The Annals of Family Medicine Jul 2004, 2 (4) 351-355; DOI: 10.1370/afm.79

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Get Permissions
Share
Subclinical Hypothyroidism and the Risk of Hypercholesterolemia
William J. Hueston, William S. Pearson
The Annals of Family Medicine Jul 2004, 2 (4) 351-355; DOI: 10.1370/afm.79
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Thyroid Hormones and Cardiovascular Function and Diseases
  • Subclinical hypothyroidism and dyslipidemia in children and adolescents with type 1 diabetes mellitus
  • TSH and free thyroxine concentrations are associated with differing metabolic markers in euthyroid subjects
  • Questions, Interpretation, Exhortation
  • In This Issue: Practice Change and Patient Safety
  • Google Scholar

More in this TOC Section

  • Teamwork Among Primary Care Staff to Achieve Regular Follow-Up of Chronic Patients
  • Shared Decision Making Among Racially and/or Ethnically Diverse Populations in Primary Care: A Scoping Review of Barriers and Facilitators
  • Convenience or Continuity: When Are Patients Willing to Wait to See Their Own Doctor?
Show more Original Research

Similar Articles

Subjects

  • Domains of illness & health:
    • Chronic illness
    • Disease pathophysiology / etiology
  • Person groups:
    • Older adults
  • Methods:
    • Quantitative methods

Content

  • Current Issue
  • Past Issues
  • Early Access
  • Plain-Language Summaries
  • Multimedia
  • Podcast
  • Articles by Type
  • Articles by Subject
  • Supplements
  • Calls for Papers

Info for

  • Authors
  • Reviewers
  • Job Seekers
  • Media

Engage

  • E-mail Alerts
  • e-Letters (Comments)
  • RSS
  • Journal Club
  • Submit a Manuscript
  • Subscribe
  • Family Medicine Careers

About

  • About Us
  • Editorial Board & Staff
  • Sponsoring Organizations
  • Copyrights & Permissions
  • Contact Us
  • eLetter/Comments Policy

© 2025 Annals of Family Medicine